Table 5.
Biomarkers as outcome measures in phase II and phase III trials for agents in the Alzheimer's disease drug development pipeline (clinicaltrials.gov; 1/5/2017)
| Biomarker | N of trials (%) |
|
|---|---|---|
| Phase III | Phase II | |
| CSF amyloid | 12 (28.6) | 17 (25.0) |
| CSF tau | 13 (31.0) | 16 (23.5) |
| FDG-PET | 5 (11.9) | 10 (14.7) |
| vMRI | 9 (21.4) | 6 (8.8) |
| Plasma amyloid | 4 (9.5) | 5 (7.4) |
| Plasma tau | 0 | 1 (1.5) |
| Amyloid PET | 13 (31.0) | 6 (8.8) |
| Tau PET | 1 (2.4) | 0 |
Abbreviations: CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; PET, positron emission tomography; vMRI, volumetric magnetic resonance imaging.